Inotec Secures £26m Series C Funding for Global Expansion

Inotec AMD, a leader in advanced wound care solutions, has successfully raised £26 million in a Series C funding round. This financial support, orchestrated by key investors Amadeus Capital Partners, Meltwind, Puhua Capital, and the Wealth Club, aims to secure national reimbursement in the United States for NATROX O, their flagship product utilizing continuous topical oxygen therapy (cTOT) to enhance the healing of chronic wounds. Inotec AMD has pledged to use these funds to expand their leadership team globally and drive innovation in wound care products. The company, known for its commitment to patient-centric solutions, has seen considerable success, with NATROX O now authorized for sale in 46 countries. The global impact of their innovation is underlined by the substantial healthcare costs associated with chronic wound management, which in the US alone amount to approximately $97 billion annually. The investment reflects investor confidence in the company's capacity to revolutionize wound care, providing impactful improvements in patient outcomes worldwide.